Beyond Platelet Counts: Evaluating Clinical Challenges and Treatment Approaches for Patients Living with ITP
Catherine M. Broome, MD, discusses how immune thrombocytopenia (ITP) is diagnosed, classified, and managed, including bleeding risk assessment, quality of life impacts, personalized treatment approaches, and future directions for addressing this heterogeneous autoimmune disorder that causes low platelet counts.
Episodes
June 6th 2025EP. 2: Diagnostic and Patient Education Strategies in ITP
A panelist discusses how ITP diagnosis remains one of exclusion requiring thorough testing to rule out other causes of thrombocytopenia, followed by patient education about autoimmune diseases and bleeding symptoms like nosebleeds, bruising, and petechiae.
June 27th 2025EP. 5: Tailoring Care in ITP Through a Health Equity Lens
A panelist discusses how personalized ITP care requires open conversations about testing costs, insurance coverage, and treatment accessibility, with clinicians helping patients navigate financial barriers through pharmaceutical assistance programs and clinical trials.
July 4th 2025EP. 6: Looking Ahead in ITP: Addressing Unmet Needs and Embracing Innovation
A panelist discusses how personalized ITP care requires open conversations about testing costs, insurance coverage, and treatment accessibility, with clinicians helping patients navigate financial barriers through pharmaceutical assistance programs and clinical trials.
July 31st 2025EP. 7: Key Clinical Signs and Symptoms Used in Diagnosis of Immune Thrombocytopenia
An expert discusses the clinical presentation and diagnosis of immune thrombocytopenic purpura (ITP), emphasizing that isolated thrombocytopenia with mucosal bleeding and petechiae is highly suggestive of ITP, while underscoring the importance of ruling out other causes—especially drug-induced thrombocytopenia—through careful evaluation.
July 31st 2025EP. 8: Clinical Decision-Making in ITP: Timing Treatment Initiation and Therapy Goals
An expert discusses treatment strategies for immune thrombocytopenic purpura (ITP), emphasizing individualized decisions based on platelet count, bleeding symptoms, and comorbidities, with options ranging from observation to urgent therapies like steroids or IVIG, and longer-term approaches tailored to patient health, treatment goals, and lifestyle considerations.
